| Bioactivity | BAY 36-7620 is a potent and noncompetitive antagonist of mGlu1 Receptor (IC50=0.16 μM) with inverse agonist activity. BAY 36-7620 inhibits tumor growth and prolongs the survival of mice with tumors by inhibiting mGlu1 receptor. BAY 36-7620 suppresses AKT phosphorylation in A549 tumors. BAY 36-762 has neuroprotective effect in acute subdural hematoma rat model.BAY 36-7620 is used in non-small cell lung cancer and breast cancer research[1][2][3][4]. |
| Invitro | BAY 36-7620 (0.1-10 μM) 在浓度 10 μM 时完全抑制了 HEK 293 细胞中的 mGlu1 受体[1] 0 --> BAY 36-7620 相关抗体: Western Blot Analysis[2] Cell Line: |
| In Vivo | BAY 36-7620 (5-10 mg/kg，腹腔注射；每日 1 次，连续 24 天) 抑制了胸腺裸鼠模型的肿瘤生长，延长了肺癌肿瘤小鼠的寿命[2]。BAY 36-7620 (0.01-0.03 mg/kg，静脉注射；4 小时) 对急性硬膜下血肿大鼠模型具有神经保护作用[4]。 Animal Model: |
| Name | BAY 36-7620 |
| CAS | 232605-26-4 |
| Formula | C19H18O2 |
| Molar Mass | 278.35 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Carroll FY, et al. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol Pharmacol. 2001 May;59(5):965-73. [2]. Xia H, et al. Inhibition of metabotropic glutamate receptor 1 suppresses tumor growth and angiogenesis in experimental non-small cell lung cancer. Eur J Pharmacol. 2016 Jul 15;783:103-11. [3]. Dolfi SC, et al. Riluzole exerts distinct antitumor effects from a metabotropic glutamate receptor 1-specific inhibitor on breast cancer cells. Oncotarget. 2017 Jul 4;8(27):44639-44653. [4]. De Vry J, et al. Neuroprotective and behavioral effects of the selective metabotropic glutamate mGlu(1) receptor antagonist BAY 36-7620. Eur J Pharmacol. 2001 Oct 5;428(2):203-14. |